Headquartered in Redwood City, CA·Fiscal year ends December·NASDAQ: CHRS·coherus.com
About Coherus Oncology
Coherus Oncology (Nasdaq: CHRS) is a commercial-stage oncology company. It sells LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor and the only FDA-approved and available U.S. treatment for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC). LOQTORZI is the NCCN's only preferred Category 1 first-line option with cisplatin and gemcitabine and its only preferred subsequent-line treatment.
The company exited its biosimilar business in 2025. Its strategy now rests on two pillars:
- growing LOQTORZI sales in NPC;
- developing two mid-stage antibody immunotherapy candidates in combination with LOQTORZI.
The two candidates are:
- tagmokitug, a selective cytolytic anti-CCR8 antibody that depletes tumor regulatory T cells, now prioritized for esophageal cancer (ESCC and EAC) and also being studied in prostate cancer with pasritamig;
- casdozokitug, an IL-27 antagonist in a Phase 2 study in first-line hepatocellular carcinoma.
Coherus holds global rights to both candidates and plans ex-U.S. licensing deals as clinical data support them. In November 2026 it announced a restructuring that cuts headcount by about 30% to lower cash burn. Updated
Pre-Market Stock Futures: Futures are trading lower as we get set to start the new trading week, as reports indicate that President Trump declined Iran’s counteroffer for peace. This comes after a…
Coherus Oncology (Nasdaq: CHRS) is a commercial-stage oncology company. It sells LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor and the only FDA-approved and available U.S. treatment for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC).
What is the CHRS stock price target?
The Wall Street consensus 12-month price target for CHRS is $7.25.